Safety and efficacy of nivolumab plus TKI combinations in advanced kidney cancer

A phase 1 study has evaluated the safety and efficacy of nivolumab in combination with sunitinib and pazopanib in people with advanced renal cell carcinoma (RCC). Although there were good responses to the nivolumab plus sunitinib  and nivolumab plus pazopanib combinations and progression-free survival (PFS) was encouraging (12.7 and 7.2 months respectively), the side effect […]

read more

Cabozantinib for the treatment of non-clear cell kidney cancer

A recent study published in the European Journal of Cancer shows that cabozantinib produced a clinically meaningful benefit in people with metastatic non-clear cell renal cell carcinoma (RCC), most of whom had disease progression on prior vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). In this retrospective study, 30 patients with metastatic non-clear cell […]

read more

A type of white blood cell as a potential biomarker to predict response to TKIs and overall survival

A study investigating the prognostic and predictive value of a type of white blood cell called tumour-infiltrating B lymphocytes for tyrosine kinase inhibitor (TKI) therapy in people with metastatic renal cell carcinoma (mRCC) has been published in the journal OncoImmunology recently. These results from the study showed that people with mRCC who were positive for […]

read more

ESMO 2018: Axitinib for the treatment of metastatic papillary renal cell carcinoma in the first-line

The results from a phase 2 clinical trial to assess the safety and efficacy of axinitib as a first-line treatment for patients with papillary renal cell carcinoma (pRCC) were presented at the European Society of Medical Oncology (ESMO) 2018 Congress in Munich over the weekend. The majority of renal cell carcinomas (RCCs) are a subtype […]

read more

Avelumab plus axitinib combination shows promise

A clinical trial looking at the combination of avelumab plus axitinib for renal cell carcinoma (RCC), JAVELIN Renal 101, has released some positive top-line results, which will be presented at an upcoming medical congress. JAVELIN Renal 101 is a pivotal phase III study with 886 renal cancer patients. As part of a planned interim analysis, […]

read more

Stereotactic body radiotherapy may improve control of localised kidney cancer

A recent study published in The Journal of Urology this month suggests that stereotactic body radiotherapy (SBRT) may be a safe and effective therapeutic option that could control the growth of localised, small numbers of metastases (oligometastatic) in people with advanced renal cell carcinoma (RCC). Fifty-eight RCC patients, who had undergone surgery and had a maximum […]

read more

Potential biomarkers may predict response to TKIs in metastatic kidney cancer

A recent study published in Clinical Cancer Research and conducted in France has identified potential biological markers that are related to the formation of new blood vessels (angiogenesis) and regulated by the levels of oxygen reaching the tissues (hypoxia). These biomarkers have been found to be strong predictors of response, progression-free survival (PFS), and overall survival […]

read more

Axitinib for metastatic non-clear cell renal cell carcinoma

Results from a phase 2 clinical trial of axitinib (Inlyta) for patients with advanced non-clear cell renal cell carcinoma (RCC) who had failed prior treatment with temsirolimus (Torisel) are promising in terms of objective response rate (ORR) and progression-free survival (PFS).  Forty patients with metastatic or recurrent non-clear cell RCC who had failed treatment with […]

read more

Axitinib plus pembrolizumab combination shows promise for advanced kidney cancer

Data from a recent phase 1b study has shown that a combination of axitinib and pembrolizumab treatment for advanced renal cell carcinoma (RCC) is safe and tolerable, and exhibits promising anti-tumour activity in previously untreated patients. The study data were presented at the 2018 Genitourinary Cancers Symposium held in San Francisco last week. The researchers […]

read more

New first-line treatment option for advanced kidney cancer available on the NHS

Today, the National Institute for Health and Care Excellence (NICE) have recommended tivozanib (Fotivda) as a new first-line treatment option for people with advanced renal cell carcinoma (RCC) for use within NHS England and Wales. This follows a protracted appraisal process involving three committee meetings over 20 months while the process was suspended to allow the manufacturer to submit further […]

read more
Showing 91 to 100 of 100 results
  TOP